2-(3,5-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane | 2094504-03-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3,5-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• 英文别名: 3,5-Difluoro-4-methylphenylboronic acid pinacol ester
• CAS: 2094504-03-5
• 化学式: C₁₃H₁₇BF₂O₂
• 分子量: 254.085
• InChiKey: WEFLGURYLOQWJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.57
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3,5-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 在 oxone||potassium monopersulfate triple salt 作用下， 以 水 、 丙酮 为溶剂， 以81 %的产率得到3,5-difluoro-4-methylphenol
  参考文献：
  名称：

  [EN] 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS DE CYCLOBUTYLE 1,3-SUBSTITUÉS ET LEURS UTILISATIONS

  摘要：

  本文提供了化合物和药物组合物，用于治疗由TRPV1受体介导的疾病或疾病。本发明还提供了通过向需要治疗的受体施用公式（I）的化合物或本文所述的药物组合物的治疗方法，用于治疗眼部疾病或疾病的方法。 (I)

  公开号：

  WO2022201097A1
• 作为产物：
  描述：

  4-溴-2,6-二氟甲苯 、 联硼酸频那醇酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 以68 %的产率得到2-(3,5-difluoro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
  参考文献：
  名称：

  [EN] 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS DE CYCLOBUTYLE 1,3-SUBSTITUÉS ET LEURS UTILISATIONS

  摘要：

  本文提供了化合物和药物组合物，用于治疗由TRPV1受体介导的疾病或疾病。本发明还提供了通过向需要治疗的受体施用公式（I）的化合物或本文所述的药物组合物的治疗方法，用于治疗眼部疾病或疾病的方法。 (I)

  公开号：

  WO2022201097A1

文献信息

• Cobalt-Catalyzed Regioselective Borylation of Arenes: N-Heterocyclic Silylene as an Electron Donor in the Metal-Mediated Activation of C−H Bonds
  作者：Hailong Ren、Yu-Peng Zhou、Yunping Bai、Chunming Cui、Matthias Driess

  DOI：10.1002/chem.201605937

  日期：2017.4.27

  C−H Borylation of arenes has been a subject of great interest recently because of its atom‐economy and the wide applicability of borylated products in value‐added synthesis. A new bis(silylene)cobalt(II) complex bearing a bis(N‐heterocyclic silylene)‐pyridine pincer ligand (SiNSi) has been synthesized and structurally characterized. It enabled the regioselective catalytic C−H borylation of pyridines

  由于芳烃的原子经济性和硼酸盐化产物在增值合成中的广泛应用，近年来，芳烃的CH硼化已引起人们极大的兴趣。合成了一种新的带有双（N-杂环甲硅烷基）-吡啶钳式配体（SiNSi）的双（甲硅烷基）钴（II）配合物，并对其结构进行了表征。它使吡啶，呋喃和氟化芳烃的区域选择性催化CH硼化成为可能。值得注意的是，与以前已知的催化体系相比，它对氟化芳烃的硼化具有互补的区域选择性，这表明N杂环亚甲硅烷基供体在金属催化的催化应用中具有巨大的潜力。
• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEL INHIBITEUR DE GALECTINES DU TYPE GALACTOSIDE
  申请人：GALECTO BIOTECH AB

  公开号：WO2021001538A1

  公开（公告）日：2021-01-07

  The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of inflammation; Inflammation induced thrombosis; Atopic dermatitis; Acute coronary syndrome; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart; local fibrosis such as Dupuytren's disease and Peyronie's disease; fibrotic complications of other therapies such as coronary stents, bile duct stents, cerebral artery stents, ureter stents; scleroderma; scarring; keloid formation; covid-19; acute lung injury; ARDS; viral pneumonitis, aberrant scar formation; surgical adhesions; septic shock; cancer, such as colorectal cancer, other gastrointestinal carcinomas such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancers, mesothelioma, female cancers like breast cancer, ovarian cancer, uterine cancer, cancer of the cervix uteri, cancer of the salpingx, cerebral cancers such as medulloblastomao, glioma, meningioma, sarcomas of the bones and muscles and other sarcomas, leukemias and lymphomas, such as T-cell lymphomas; transplant rejection; metastasising cancers; ageing; Dementia; Alzheimers; TGFbeta driven bone disease such as osteogenesis imperfecta; Pulmonary hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Rheumatoid lung; Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, Herpes virus, Coronaviruses, Hepatitis C; metabolic disorders; heart disease; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistens; obesity; Marfans syndrome; Loeys–Dietz syndrome; nephropathy; Diastolic HF; fibrotic lung complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, liver disorders, such as non- alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine disease such as uterine fibroids and uterine or cervical fibrosis.

  本发明涉及一种化学式（1）中的D-半乳糖吡喃糖类化合物，其中吡喃糖环为α-D-半乳糖吡喃糖，这些化合物是高亲和力的galectin-3抑制剂，用于治疗炎症；炎症诱导性血栓形成；特应性皮炎；急性冠状动脉综合征；纤维化，如肺纤维化、肝脏纤维化、肾脏纤维化、眼科纤维化和皮肤和心脏的纤维化；局部纤维化，如杜普伊特伦氏病和佩罗尼氏病；其他治疗的纤维化并发症，如冠状支架、胆管支架、脑动脉支架、输尿管支架；硬皮病；瘢痕形成；瘢痕增生；新冠肺炎；急性肺损伤；ARDS；病毒性肺炎；异常瘢痕形成；手术粘连；脓毒性休克；癌症，如结直肠癌、其他胃肠道癌症如胰腺癌、胃癌、胆道癌、肺癌、间皮瘤、女性癌症如乳腺癌、卵巢癌、子宫癌、宫颈癌、输卵管癌、脑癌如髓母细胞瘤、胶质瘤、脑膜瘤、骨骼和肌肉的肉瘤和其他肉瘤、白血病和淋巴瘤，如T细胞淋巴瘤；移植排斥；转移性癌症；衰老；痴呆症；阿尔茨海默病；TGFbeta驱动的骨疾病，如骨发育不全；肺动脉高压；自身免疫疾病，如牛皮癣、类风湿关节炎、类风湿肺；克罗恩病、溃疡性结肠炎、强直性脊柱炎、系统性红斑狼疮；病毒感染，如流感病毒、HIV、疱疹病毒、冠状病毒、丙型肝炎；代谢紊乱；心脏病；心力衰竭；病理性血管生成，如眼部血管生成或与眼部血管生成相关的疾病或症状，例如与癌症相关的新血管生成；眼部疾病，如老年性黄斑变性和角膜新血管生成；动脉粥样硬化；代谢性疾病；糖尿病；1型糖尿病；2型糖尿病；胰岛素抵抗；肥胖；马凡氏综合征；洛伊斯-迪茨综合征；肾病；舒张期心力衰竭；PD1和其他CPI疗法的肺纤维化并发症；哮喘和其他间质性肺疾病，包括赫尔曼斯基-普德拉克综合征、肝脏疾病，如非酒精性脂肪性肝炎或非酒精性脂肪肝病；子宫疾病，如子宫肌瘤和子宫或宫颈纤维化。
• Iridium‐Catalysed C−H Borylation of Fluoroarenes: Insights into the Balance between Steric and Electronic Control of Regioselectivity
  作者：Mingyan Ding、Jonathan A. Reuven、Andrew C. Hones、Mark A. Fox、Patrick G. Steel

  DOI：10.1002/ejoc.202201005

  日期：2022.12.19

  Iridium catalysed C−H borylation provides an effective method for late stage functionalization of fluorinated arenes and heteroarenes. The reaction occurs rapidly and efficiently with selectivity that can be best predicted using computed relative transition stage energies.

  铱催化的 C−H 硼酸化为氟化芳烃和杂芳烃的后期功能化提供了一种有效的方法。反应快速有效地发生，选择性可以使用计算的相对过渡阶段能量进行最佳预测。